Health Condition 1: L40- Psoriasis
Conditions
Interventions
Intervention1: drugs - Tofacitinib: group B will recieve Tofacitinib 5 mg OD
Control Intervention1: drugs - apremilast: group A will recieve apremilast 30 mg OD
Sponsors
none
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis: Chronic plaque psoriasis patient with active disease of duration of more than one year. Body surface area (BSA) involvement is less than 10%. Participants must be adult (18 years or older) of any sex, presenting to the Dermatology OPD. Participants providing written informed consent.
Exclusion criteria
Exclusion criteria: Patients unwilling to give written informed consent to participate in the study. Patients of Psoriasis with other major dermatological ailments (Immunobullous disease, SLE, Connective tissue diseases, Autoimmune diseases, Vitiligo, Vasculitis). Patients with underlying hepatic, renal diseases, coronary artery disease (CAD) or any major contraindications to the use of tofacitinib or apremilast. Pregnant, lactating females. Patient who are currently receiving or have received other systemic medication for the treatment of psoriasis in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall effective rate: Number of patients achieving PASI 75 at the end of treatment (12 weeks) within group A and B/Total number of patients.Timepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| PASI,DLQI scores will be reviewed 4 weekly (0, 4, 8, 12, 16, 20, 24). sPGA, PSS scores will be recorded before & after treatment (12 weeks) & follow-up at 24 weeks. sPGA, PSS scores will be recorded before & after treatment (12 weeks) & follow-up at 24 weeks.Timepoint: baseline 0 week, 4 weeks, 8 weeks , 12weeks , 16 weeks , 20 weeks , 24 weeks | — |
Countries
India
Contacts
Public Contactpurva
AIIMS Rajkot
Outcome results
None listed